The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis. (Q51632815)

8 April 2018

meta-analysis

0 references

title

The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis. (English)

1 reference

8 April 2018

1 reference

Duo Liu

1

1 reference

8 April 2018

Yuyang Tian

2

1 reference

8 April 2018

Donglin Sun

3

1 reference

8 April 2018

Haiming Sun

4

1 reference

8 April 2018

Yan Jin

5

1 reference

8 April 2018

Mei Dong

6

1 reference

8 April 2018

publication date

19 July 2016

1 reference

8 April 2018

published in

Annals of Hematology

1 reference

8 April 2018

volume

95

1 reference

8 April 2018

issue

9

1 reference

8 April 2018

page(s)

1483-1490

1 reference

8 April 2018

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

FCGR3A polymorphism story: a new piece of the puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-016-2723-X

10.1007/S00277-016-2723-X

21 January 2018

Identifiers

DOI

1 reference

8 April 2018

PubMed ID

27431582

1 reference

8 April 2018